Author of

• 36336

  +

  P76 - Targeted Therapy - Clinically Focused - EGFR (ID 253)

  • Event: WCLC 2020
  • Type: Posters
  • Track: Targeted Therapy - Clinically Focused
  • Presentations: 1
  • Moderators:
  • Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall

  • 36363

    +

    P76.23 - A Retrospective Study of Non-Small Cell Lung Cancer Treated with Second- and Third-Generation EGFR Tyrosine Kinase Inhibitors (ID 1347)

    00:00 - 00:00  |  Presenting Author(s): SHO Mitsuya
    • Abstract
    • Slides

    Introduction
    

    Various clinical trials have evaluated first- to third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) as the first-line treatment for EGFR-mutated non-small cell lung cancer (NSCLC). Although recent research evidence supports the use of third-generation TKIs such as osimertinib as therapeutic agents for patients with EGFR-mutated NSCLC, there are no reports of clinical trials comparing second-generation such as afatinib and third-generation TKIs. Further prospective evaluation is required.

    Methods
    

    Clinical research data from the Osaka Medical College Hospital were retrospectively analyzed. All patients diagnosed with EGFR-mutated NSCLC who were treated with afatinib or osimertinib as first-line treatment from January 2015 to December 2019 were included. Systemic progression-free survival (PFS) and overall survival (OS) were evaluated.

    Results
    

    A total of 47 patients were included in this study. Of these, 13 patients received afatinib and 34 osimertinib. Patients on afatinib treatment had a median age of 68; 7 were male and 6 were female. Patients on osimertinib treatment had a median age of 72; 14 were male and 20 were female. The performance status (0/1/≧2) of afatinib and osimertinib was 4/9/0 and 6/25/3, respectively. The type of EGFR mutation (Exon 19 deletion/L858R/Others) differed between afatinib (6/4/3) and osimertinib (14/17/3). Progression-free survival analysis indicated no significant differences between the two groups: afatinib 18 months vs. osimertinib, which could not be calculated (hazard ratio = 0.576; 95% confidence interval = 0.171-1.941; P=0.356). Overall survival in months was calculated: afatinib could not be calculated vs. 33 months for osimertinib (hazard ratio = 1.981; 95% confidence interval = 0.348-11.273; P=0.422). Afatinib was superior to osimertinib in the objective response rate (afatinib, 76.9% vs. osimertinib, 64.7%). Severe adverse events (grade≧3) were more reported for afatinib than for osimertinib (23.1% vs. 14.7%).

    Conclusion
    

    Second- and third-generation TKIs are both appropriate first-line treatments for EGFR-mutated NSCLC.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.